receptorbind
domain
rbd
spike
protein
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
main
region
interact
viral
use
target
induct
neutral
antibodi
sarscov
infect
gener
two
monoclon
antibodi
mab
target
rbd
mark
viru
neutral
activ
mab
recogn
new
conform
epitop
consist
sever
discontinu
peptid
aa
spatial
locat
neighbor
receptorbind
motif
rpm
region
rbd
importantli
residu
essenti
mab
recognit
highli
conserv
among
differ
strain
sar
indic
residu
critic
epitop
novel
potenti
target
therapeut
mab
humanmous
chimer
antibodi
base
upon
origin
murin
mab
also
construct
shown
possess
good
neutral
activ
high
affin
abbrevi
sar
sever
acut
respiratori
syndrom
sarscov
sever
acut
respiratori
syndromeassoci
coronaviru
mabpab
monoclonalpolyclon
antibodi
rbd
receptorbind
domain
rbdfc
receptorbind
domain
link
human
igg
fc
rpm
receptorbind
motif
angiotensinconvert
enzym
cpe
cytopath
effect
pfu
plagu
form
unit
correspond
author
sever
acut
respiratori
syndrom
sar
spread
wide
china
world
result
great
loss
life
properti
fatal
diseas
caus
newli
identifi
coronaviru
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
rota
et
al
sarscov
new
kind
coronaviru
significantli
differ
previous
known
one
stadler
et
al
singlestrand
positivesens
rna
viru
contain
four
structur
protein
embed
surfac
viral
particl
stadler
et
al
among
demonstr
spike
protein
protein
import
function
protein
mediat
entri
viru
suscept
cell
protein
sarscov
type
transmembran
glycoprotein
consist
amino
acid
two
function
domain
aa
aa
predict
sequenc
align
protein
coronavirus
rota
et
al
holm
domain
mediat
viral
attach
cellular
receptor
li
et
al
function
portion
within
domain
directli
interact
identifi
receptorbind
domain
rbd
locat
aa
proven
major
neutral
determin
et
al
demonstr
rbd
induc
highli
potent
neutral
antibodi
therefor
consid
excel
candid
develop
subunit
vaccin
sar
et
al
neutral
antibodi
target
rbd
gener
direct
immun
mice
inactiv
sar
viru
rbd
protein
et
al
et
al
identif
region
contain
crucial
amino
acid
within
rbd
essenti
assur
recognit
neutral
antibodi
identif
could
help
increas
understand
neutral
mechan
aid
discoveri
potenti
drug
target
far
report
rbd
contain
sever
linear
conform
epitop
among
neutral
epitop
conform
one
also
specif
fragment
crucial
amino
acid
within
rbd
region
relat
neutral
activ
chakraborti
et
al
yi
et
al
recent
crystal
structur
rbd
complex
clearli
demonstr
receptorbind
motif
within
rbd
character
import
region
directli
contact
although
studi
mention
brought
us
much
inform
neutral
epitop
still
complet
character
particular
detail
inform
concern
conform
neutral
epitop
critic
amino
acid
limit
moreov
recent
studi
shown
rpm
import
region
recogn
neutral
monoclon
antibodi
prabakaran
et
al
hwang
et
al
howev
inform
neutral
epitop
exist
outsid
rpm
still
incomplet
studi
gener
two
neutral
monoclon
antibodi
term
rbd
exhibit
good
neutral
activ
syncytia
inhibit
assay
pseudoviru
infect
assay
neutral
assay
sar
viru
infect
cell
map
experi
indic
mab
recogn
sever
discontinu
peptid
aa
bind
activ
conformationdepend
mutat
complet
abrog
bind
activ
rbd
neutral
monoclon
antibodi
reveal
residu
within
peptid
locat
adjoin
receptorbind
motif
rbm
rbd
import
region
hold
interact
surfac
stabl
among
differ
strain
sar
song
et
al
indic
mab
would
possibl
possess
broad
neutral
spectrum
humanmous
chimer
antibodi
thu
construct
base
upon
mab
retain
high
affin
kd
compar
origin
murin
mab
kd
addit
maintain
bind
specif
neutral
activ
present
work
describ
discoveri
new
conform
epitop
rbd
locat
outsid
rpm
form
sever
discontinu
peptid
conserv
amino
acid
critic
mab
bind
site
find
help
develop
therapeut
antibodi
sarscov
order
produc
use
antigen
mimic
natur
spike
protein
particl
surfac
sarscov
full
length
gene
fig
rbdspecif
neutral
ab
induc
mice
vaccinia
viru
contain
full
length
spike
gene
use
immun
mice
titer
rbdspecif
ab
test
use
elisa
sera
collect
week
second
immun
b
c
three
individu
immun
mice
n
mous
without
immun
b
neutral
activ
measur
syncytia
inhibit
assay
immun
mous
sera
collect
week
second
booster
immun
screen
syncytia
inhibit
assay
cell
without
plasmid
transfect
posit
control
cell
transfect
plasmid
antiserum
ad
neutral
effect
normal
mous
sera
n
immun
mous
sera
b
c
measur
group
transfect
cell
mous
whose
serum
bear
highest
neutral
activ
select
rais
mab
neutral
activ
mab
b
differ
dose
determin
syncytia
inhibit
assay
method
describ
fig
mab
antiserum
cell
without
plasmid
transfect
u
antimous
mab
select
unrel
control
mab
n
mab
volum
mab
ascit
ad
well
medium
ml
also
mark
insert
vaccinia
viru
express
system
confirm
express
viru
work
well
construct
viru
use
immun
mice
subsequ
neutral
activ
result
antisera
test
syncytia
format
experi
neutral
activ
sera
establish
appropri
mous
select
rais
mab
gener
neutral
mab
high
effici
region
cover
receptorbind
domain
rbd
gene
fuse
human
igg
fc
fragment
util
screen
antigen
experi
show
mice
immun
vaccinia
viru
develop
remark
antibodi
respons
rbd
protein
fig
antibodi
titer
serum
significantli
enhanc
follow
booster
immun
data
shown
one
week
second
immun
antiserum
collect
test
neutral
activ
use
syncytia
inhibit
assay
result
show
vaccinia
viru
immun
induc
consider
concentr
neutral
antibodi
block
bind
activ
protein
fig
suggest
vaccinia
viru
antigen
could
trigger
signific
neutral
antibodi
respons
target
rbd
region
mab
possess
high
affin
signific
neutral
activ
select
hybridoma
clone
react
rbd
domain
select
data
shown
two
clone
exhibit
neutral
activ
confirm
syncytia
format
inhibit
assay
fig
b
chosen
term
isotyp
analyz
found
igg
igg
belong
igg
class
ascit
produc
mab
possess
high
titer
indic
bind
rbd
elisa
dilut
rate
reach
data
demonstr
mab
rais
studi
high
affin
exhibit
potenti
inhibitori
effect
block
interact
sarscov
spike
protein
base
upon
primari
data
gener
syncytia
inhibit
experi
suggest
mab
like
possess
potenti
neutral
activ
order
confirm
notion
two
method
select
evalu
neutral
activ
initi
pseudotyp
viru
assay
util
result
indic
signific
inhibit
pseudoviru
infect
achiev
use
mab
fig
experi
reveal
mab
could
block
infect
sar
pseudoviru
target
vero
cell
interfer
protein
interact
secondli
evalu
neutral
activ
mab
sar
virusinfect
cell
serial
dilut
begin
carri
arriv
highest
dilut
rate
allow
complet
suppress
cpe
induc
viru
least
well
mab
ascit
test
show
mark
neutral
effect
upon
sar
viru
infect
dilut
titer
addit
experi
mab
ascit
show
similar
neutral
effect
data
shown
result
strongli
indic
mab
potenti
use
candid
therapeut
use
sar
infect
base
upon
primari
data
suggest
high
affin
mark
neutral
activ
mab
compar
mab
data
shown
interest
map
epitop
recogn
mab
first
carri
elisa
experi
determin
whether
epitop
recogn
mab
might
linear
conform
result
show
rbdfc
protein
denatur
heat
bind
activ
mab
antigen
complet
lost
fig
indic
epitop
conformationdepend
sinc
rbd
domain
locat
amino
acid
residu
recogn
mab
seri
synthet
overlap
peptid
total
cover
entir
rbd
sequenc
select
tabl
experi
perform
identifi
specif
region
amino
acid
crucial
bind
mab
rbd
initi
synthet
peptid
coat
plate
reactiv
mab
test
elisa
unexpectedli
reactiv
undetect
data
shown
subsequ
dotblot
experi
employ
guarante
success
first
test
overlap
peptid
laboratoryprepar
rabbit
antispik
polyclon
antibodi
recogn
protein
amino
acid
residu
wu
et
al
result
show
polyclon
antibodi
clearli
recogn
sever
peptid
differ
bind
intens
depend
upon
differ
antigen
fig
expect
pab
react
ha
peptid
neg
control
data
demonstr
util
system
experi
abl
identifi
three
major
antigen
region
peptid
aa
aa
aa
fig
test
bind
activ
mab
peptid
result
show
mab
abl
bind
peptid
repres
amino
acid
residu
tabl
fig
c
peptid
posit
also
demonstr
mild
bind
signal
weak
consid
recogniz
also
shown
two
mab
recogn
peptid
indic
share
epitop
although
mab
recogn
conform
epitop
still
abl
use
dotblot
analysi
detect
peptid
reactiv
analyz
epitop
recogn
mab
within
whole
rbd
region
construct
computerbas
model
variabl
region
mab
predict
interact
pattern
rbd
base
upon
analysi
sever
cluster
amino
acid
residu
rbd
select
fig
combin
dotblot
experi
comput
predict
predict
five
site
vad
vl
ff
wn
rni
might
import
mab
bind
fig
sitedirect
mutat
experi
carri
test
whether
put
site
could
influenc
bind
mutat
amino
acid
five
site
alanin
tabl
gener
mutat
rbdfc
transient
transfect
determin
bind
activ
mab
use
sandwich
elisa
fig
result
show
mutat
rbdfc
lost
signific
abil
bind
mab
indic
two
amino
acid
crucial
bind
mab
rbd
final
determin
degre
variat
two
amino
acid
residu
differ
sar
strain
chose
sar
spike
gene
among
palm
civet
song
et
al
conserv
sar
gene
sequenc
without
mutat
result
indic
mab
would
probabl
broad
viral
neutral
spectrum
epitop
highli
conserv
among
differ
sar
strain
structur
rbd
offer
direct
precis
profil
newli
identifi
neutral
epitop
peptid
identifi
dot
blot
analysi
form
rbd
spatial
structur
local
immedi
besid
rpm
region
fig
interestingli
first
amino
acid
residu
determin
rpm
although
neutral
epitop
well
local
surfac
directli
contact
antibodi
abl
bind
region
block
attach
due
spatial
hindranc
explain
neutral
mechan
two
mab
molecular
level
construct
chimer
antibodi
base
upon
clone
retain
affin
specif
neutral
activ
murin
mab
data
show
chimer
antibodi
recogn
peptid
murin
antibodi
dotblot
assay
indic
chimer
natur
antibodi
chang
bind
specif
fig
spr
experi
carri
determin
bind
affin
chimer
antibodi
rbd
data
indic
chimer
antibodi
murin
mab
show
high
bind
affin
rbd
kd
respect
high
affin
explain
strong
neutral
effect
mab
doubt
construct
chimer
antibodi
complet
preserv
bind
affin
murin
mab
addit
test
neutral
activ
chimer
antibodi
pseudoviru
infect
system
result
reveal
chimer
antibodi
similar
function
murin
one
complet
block
entri
pseudoviru
vero
cell
concentr
data
shown
data
indic
success
construct
sar
chimer
neutral
antibodi
great
potenti
therapeut
use
sar
infect
studi
demonstr
receptorbind
domain
sarscov
play
crucial
role
process
viral
infect
host
immun
respons
especi
domin
antigen
induc
neutral
antibodi
develop
inform
concern
epitop
rbd
report
reveal
rbd
contain
variou
linear
conform
epitop
neutral
epitop
conform
one
although
neutral
antibodi
show
higher
affin
spatial
profil
conform
epitop
well
understood
also
studi
function
import
amino
acid
segment
rbd
report
delet
posit
charg
region
rbd
protein
abolish
capac
protein
induc
neutral
antibodi
also
report
singl
amino
acid
substitut
fulllength
dna
vaccin
fail
induc
neutral
antibodi
abolish
viral
entri
result
indic
particular
portion
amino
acid
rbd
crucial
retain
rbd
normal
function
howev
whether
critic
amino
acid
segment
exist
conform
neutral
epitop
still
known
crystal
structur
complex
identifi
introduc
detail
inform
concern
rbd
structur
function
structur
reveal
rbd
could
divid
separ
subdomain
one
rbd
core
rbd
loop
rpm
aa
rbd
loop
region
directli
contact
molecul
rbd
core
hand
make
contact
accessori
protein
epitop
recogn
human
neutral
monoclon
antibodi
map
crucial
amino
acid
residu
rbd
loop
region
bind
neutral
mab
determin
sui
et
al
sui
et
al
howev
littl
evid
descript
report
regard
epitop
especi
conform
one
locat
outsid
rbd
loop
region
current
import
task
character
neutral
epitop
clarifi
spatial
profil
determin
import
region
amino
acid
involv
neutral
antibodi
recognit
neutral
epitop
conform
one
meaning
develop
suitabl
strategi
studi
structur
identifi
critic
amino
acid
given
antigen
studi
report
first
time
conform
neutral
epitop
local
outsid
rpm
region
indic
neutral
antibodi
bind
surfac
interact
also
bind
site
ultim
three
peptid
aa
seen
form
conform
epitop
within
amino
acid
peptid
central
point
mab
recognit
elicit
neutral
antibodi
research
process
notabl
peptiderel
dotblot
method
use
analyz
conform
epitop
result
indic
neutral
mab
recogn
naturalconformationdepend
antigen
bind
mild
affin
peptid
could
detect
dotblot
method
mani
clone
neutral
monoclon
antibodi
target
protein
rais
far
varieti
method
util
exampl
tradit
peg
cell
fusion
method
phage
display
method
sui
et
al
chou
et
al
brink
et
al
antigen
immun
includ
inactiv
whole
viru
recombin
protein
rbdfc
protein
et
al
chou
et
al
zhou
et
al
use
modifi
recombin
vaccinia
viru
ankara
sar
protein
surfac
antigen
immun
mice
result
show
vaccinia
viru
abl
elicit
high
titer
neutral
antibodi
therefor
appear
ideal
immun
antigen
gener
monoclon
antibodi
well
possibl
vaccin
candid
screen
hybridoma
clone
use
mammaliancel
express
rbdfc
protein
whose
natur
conform
well
preserv
strategi
success
obtain
two
hybridoma
clone
gener
monoclon
antibodi
target
rbd
region
protein
high
affin
good
neutral
effect
evalu
neutral
effect
util
two
differ
system
one
syncytia
inhibit
assay
pseudoviru
infect
assay
procedur
allow
us
evalu
neutral
effect
antibodi
peptid
conveni
vitro
sinc
amino
acid
neutral
epitop
constitut
conserv
site
mab
site
thu
constitut
potenti
therapeut
mab
construct
chimer
antibodi
base
upon
murin
monoclon
antibodi
clone
chimer
antibodi
shown
specif
origin
murin
one
retain
neutral
effect
therefor
work
demonstr
feasibl
construct
neutral
chimer
antibodi
potenti
therapeut
valu
might
develop
sar
therapeut
drug
summari
mab
recogn
new
conform
epitop
rais
epitop
consist
sever
discontinu
peptid
aa
spatial
locat
near
receptorbind
motif
rpm
region
rbd
residu
peptid
essenti
mab
recognit
highli
conserv
among
differ
strain
sar
indic
residu
critic
epitop
constitut
novel
potenti
target
induc
broad
respons
neutral
mab
humanmous
chimer
antibodi
also
construct
good
neutral
activ
high
affin
base
upon
origin
murin
mab
characterist
demonstr
mab
demonstr
notabl
potenti
use
prevent
sar
infect
balbc
mice
purchas
shanghai
laboratori
anim
center
chines
academi
scienc
anim
kept
convent
condit
handl
complianc
chines
academi
scienc
guidelin
anim
care
use
recombin
modifi
vaccinia
viru
ankara
express
protein
sarscov
use
antigen
immun
modifi
sar
vaccin
show
excel
potenti
induc
neutral
antibodi
target
primarili
rbd
region
mammaliancel
express
rbdfc
serv
natur
form
protein
rbd
region
use
antigen
screen
hybridoma
clone
sixweek
old
femal
balbc
mice
use
immun
inject
quantiti
antigen
use
per
mous
pfu
intramuscular
multisit
inject
method
adopt
boost
carri
time
interv
serum
collect
day
second
immun
store
three
day
last
boost
mous
spleen
cell
harvest
fuse
myeloma
cell
line
use
peg
wv
distribut
plate
cultur
supernat
well
screen
use
elisa
antibodi
reactiv
rbd
posit
well
select
use
limit
dilut
method
three
cycl
clone
hybridoma
clone
establish
monoclon
antibodi
isotyp
identifi
use
mous
subisotyp
kit
biorad
usa
monoclon
antibodi
produc
mous
ascit
inject
hybridoma
cell
per
mous
intraperiton
purifi
protein
g
column
chromatographi
elisa
rbdfc
protein
dissolv
carbon
buffer
ph
coat
microtit
plate
overnight
block
phosphatebuff
salin
pb
contain
bovin
serum
tween
h
plate
incub
cultur
supernat
dilut
antiserum
h
bound
antibodi
detect
hrpconjug
goat
antimous
ig
antibodi
santa
cruz
usa
tetramethylbenzidin
tmb
use
substrat
sigma
usa
absorb
measur
use
microtit
plate
autoread
thermo
usa
nm
sandwich
elisa
protein
g
purifi
mab
coat
microtit
plate
block
supernat
contain
rbdfc
mutat
form
place
plate
antihuman
igg
fc
specif
hrpconjug
antibodi
sigma
usa
use
detect
antibodi
detail
protocol
describ
rbd
denatur
elisa
rbdfc
protein
rbdfc
protein
denatur
heat
min
sd
coat
elisa
microtit
plate
incub
overnight
detail
protocol
describ
assay
describ
previou
articl
brief
cotransfect
cell
approxim
confluent
mm
dish
plasmid
puhd
anoth
group
cell
approxim
confluent
mm
dish
cotransfect
puhd
luc
control
plasmid
prellina
also
util
intern
refer
twentyfour
hour
transfect
two
group
cell
trypsin
resuspend
fb
adjust
proper
final
concentr
antibodi
ascit
antiserum
obtain
mab
gener
ad
spike
protein
group
transfect
cell
serial
dose
per
well
incub
h
subsequ
two
group
cell
mix
togeth
cell
number
plate
total
cell
number
volum
ml
per
well
incub
twentyfour
hour
later
medium
aspir
cell
lyse
passiv
lysi
buffer
promega
usa
luciferas
intens
measur
use
luminomet
promega
usa
cell
plate
approxim
confluenc
plate
twentyfour
hour
later
plasmid
code
sar
spike
protein
luc
env
vpr
cotransfect
use
lipofectamin
invitrogen
usa
gener
hiv
backbon
pseudoviru
sar
spike
protein
embed
surfac
fortyeight
hour
later
supernat
collect
cell
use
low
speed
centrifug
rpm
min
aliquot
frozen
vero
cell
plate
target
cell
infect
plate
approxim
confluenc
infect
medium
aspir
pseudoviru
supernat
mix
fbsdmem
ad
per
well
simultan
without
purifi
mab
ascit
antiserum
incub
twentyfour
hour
later
anoth
ml
fbsdmem
ad
well
seventytwo
hour
infect
medium
aspir
cell
wash
pb
twice
lyse
passiv
lysi
buffer
promega
usa
room
temperatur
store
analyz
immedi
luciferas
activ
microtit
plate
use
neutral
assay
serial
twofold
dilut
mab
separ
mix
tcid
viru
incub
h
ad
cell
viru
backtitr
viru
serial
twofold
dilut
medium
viru
posit
control
tcid
neg
cell
control
medium
parallel
neutral
test
includ
assay
dilut
serum
viru
control
repeat
well
result
observ
daili
cpe
endpoint
read
record
day
viru
inocul
tcid
calcul
use
reedmuench
method
titer
neutral
antibodi
determin
base
upon
highest
dilut
mab
mab
could
complet
suppress
cpe
induc
viru
least
well
viru
experi
carri
biosafeti
laboratori
univers
hong
kong
assay
perform
identifi
bind
epitop
monoclon
antibodi
antigen
use
overlap
peptid
cover
entir
rbd
domain
aa
peptid
dilut
pb
blot
pvdf
membran
wash
five
time
ttb
membran
block
bsa
ttb
h
dilut
monoclon
antibodi
antiserum
bsa
ttb
ad
incub
overnight
subsequ
membran
incub
secondari
antibodi
goat
antimouserabbit
hrp
conjug
antibodi
santa
cruz
usa
h
blot
develop
use
ecl
western
blot
substrat
reagent
pierc
usa
computerbas
simul
structur
vhvl
region
construct
interact
model
structur
rbd
domain
carri
determin
specif
amino
acid
critic
bind
activ
first
clone
variabl
region
mab
sequenc
pdb
databas
structur
model
construct
bind
model
put
structur
alreadyknown
rbd
structur
simul
potenti
crucial
amino
acid
predict
pcr
method
use
construct
mutat
form
rbd
protein
mutat
amino
acid
construct
util
pcr
primer
pcr
mutat
form
rbd
gene
obtain
subsequ
clone
vector
human
igg
fc
tag
gene
mutat
amino
acid
specif
pcr
primer
includ
tabl
transient
mammalian
protein
express
system
use
express
rbd
protein
mutat
form
briefli
rbdfc
express
plasmid
transient
transfect
use
lipofectamin
invitrogen
usa
cell
plate
h
plate
fortyeight
hour
later
cell
harvest
lyse
ml
ripa
buffer
per
well
supernat
collect
centrifug
rpm
min
use
sandwich
elisa
assay
describ
possibl
success
detect
mab
bind
activ
rbd
mutat
form
cell
lysi
supernat
construct
mousehuman
chimer
igg
total
rna
isol
hybridoma
cell
use
tri
reagent
sigma
usa
variabl
domain
gene
obtain
polymeras
chain
reaction
pcr
revers
transcript
gel
purif
subsequ
gene
insert
pgemt
vector
promega
usa
sequenc
sangon
china
variabl
region
gene
includ
signal
sequenc
construct
plasmid
contain
human
kappa
constant
domain
human
domain
plasmid
transfect
chodhfr
cell
line
use
lipofectamin
reagent
invitrogen
usa
construct
chimericantibodysecret
cell
clone
screen
use
elisa
detect
chimer
antibodi
cultur
supernat
establish
use
limit
dilut
method
establish
stabli
transfect
clone
dotblot
procedur
use
measur
bind
specif
chimer
antibodi
spr
biacor
usa
assay
employ
character
affin
pseudoviru
infect
assay
use
determin
neutral
activ
chimer
antibodi
experi
repeat
least
twice
usual
three
time
figur
show
data
compil
sever
experi
repres
experi
specifi
result
repres
mean
sd
applic
statist
analys
parametr
data
perform
independ
ttest
